<DOC>
	<DOCNO>NCT02971930</DOCNO>
	<brief_summary>This study generate qualitative data evaluate impact frequency FVIII infusion patient ' satisfaction treatment quality life .</brief_summary>
	<brief_title>Exit Interviews Assess Impact Infusion Frequency Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Patient enrol BAY949027 extension study within 3 month complete participation BAY949027 extension study ; Patient allocate Arm 2 , Arm 3 Arm 4 BAY949027 extension study . Arm 2 Prophylaxis treatment BAY949027 ; 2 infusion per week extension study Arm 3 Prophylaxis treatment BAY949027 ; infusion every 5 day extension study Arm 4 Prophylaxis treatment BAY949027 ; every 7 day extension study Evidence personally sign date informed consent document indicate patient inform pertinent aspect study ; Patient must willing able participate telephone interview last 30 minute ; Patient must sufficient cognitive linguistic capacity allow actively participate interview last 30 minute . Patient part Arm 1 : Ondemand treatment BAY949027 individual dose number infusion base upon location severity bleeds ; Patient unlikely comply study protocol ( e.g . uncooperative attitude ) unlikely complete study reason opinion recruiter ; Patient great difficulty hear reading ; Patient significant comorbid condition ( include uncontrolled psychiatric condition ) might limit interfere ability talk Hemophilia A participate study ; Patient severe neurological cognitive deficit might affect ability participate interview .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>